Explore our case studies and learn about how Cellix built expertise in our 5 building blocks.
Cellix is involved in Platform 4 of this grant working with Trinity College Dublin, Radisens and BD Biosciences to develop a clinically relevant prototype instrument based on a magnetic barcode system (encoding, reading, multiplexing & screening) for the detection of cancer biomarkers.
NAMDIATREAM will develop a cutting edge nanotechnology-based tool kit for multi-modal detection of biomarkers of most common cancer types and cancer metastases, permitting identification of cells indicative of early disease onset in a high-specificity and throughput format in clinical, laboratory and point-of-care devices.
The project is built on the innovative concepts of super-sensitive and highly specific lab-on-a-bead , lab-on-a-chip and lab-on-a-wire nano-devices utilizing photo-luminescent, plasmonic, magnetic and non-linear optical properties of nano-materials. This offers ground-breaking advantages over present technologies in terms of stability, sensitivity, time of analysis, probe multiplexing, assay miniaturisation and reproducibility.
The ETP in nano-medicine documents point out that nanotechnology has yet to deliver practical solutions for the patients and clinicians in their struggle against common, socially and economically important diseases such as cancer. Over 3.2M new cases and 1.7M cancer-related deaths are registered in Europe every year, largely because diagnostic methods have an insufficient level of sensitivity, limiting their potential for early disease identification.
We will deliver photo-luminescent nano-particle-based reagents and diagnostic chips for high throughput early diagnosis of cancer and treatment efficiency assessment Nano-crystals enabling plasmon-optical and nonlinear optical monitoring of molecular receptors within body fluids or on the surface of cancer cell multi-parameter screening of cancer biomarkers in diagnostic material implementing segmented magnetic nano-wires.
Validation of nano-tools for early diagnosis and highly improved specificity in cancer research. OECD-compliant nano-materials with improved stability, signal strength and biocompatibility. Direct lead users of the results will be the diagnostic and medical imaging device companies involved in the consortium, clinical and academic partners.
This project has received funding from the European Commission under topic call NMP-2009-4.0-3.
Read the complete available background
Detecting Cancer using Magnetic Flow Cytometry
Explore our case studies and learn about how Cellix built expertise in our 5 building blocks.
Using magnetic barcoding to detect cancer biomarkers
The NAMDIATREAM Project
Cellix is involved in Platform 4 of this grant working with Trinity College Dublin, Radisens and BD Biosciences to develop a clinically relevant prototype instrument based on a magnetic barcode system (encoding, reading, multiplexing & screening) for the detection of cancer biomarkers.
Overall Project Aims
NAMDIATREAM will develop a cutting edge nanotechnology-based tool kit for multi-modal detection of biomarkers of most common cancer types and cancer metastases, permitting identification of cells indicative of early disease onset in a high-specificity and throughput format in clinical, laboratory and point-of-care devices.
The project is built on the innovative concepts of super-sensitive and highly specific lab-on-a-bead , lab-on-a-chip and lab-on-a-wire nano-devices utilizing photo-luminescent, plasmonic, magnetic and non-linear optical properties of nano-materials. This offers ground-breaking advantages over present technologies in terms of stability, sensitivity, time of analysis, probe multiplexing, assay miniaturisation and reproducibility.
The ETP in nano-medicine documents point out that nanotechnology has yet to deliver practical solutions for the patients and clinicians in their struggle against common, socially and economically important diseases such as cancer. Over 3.2M new cases and 1.7M cancer-related deaths are registered in Europe every year, largely because diagnostic methods have an insufficient level of sensitivity, limiting their potential for early disease identification.
We will deliver photo-luminescent nano-particle-based reagents and diagnostic chips for high throughput early diagnosis of cancer and treatment efficiency assessment Nano-crystals enabling plasmon-optical and nonlinear optical monitoring of molecular receptors within body fluids or on the surface of cancer cell multi-parameter screening of cancer biomarkers in diagnostic material implementing segmented magnetic nano-wires.
Validation of nano-tools for early diagnosis and highly improved specificity in cancer research. OECD-compliant nano-materials with improved stability, signal strength and biocompatibility. Direct lead users of the results will be the diagnostic and medical imaging device companies involved in the consortium, clinical and academic partners.
Interested to learn more?
NAMDIATREAM Project Information
Project Details
Contact Us
This project has received funding from the European Commission under topic call NMP-2009-4.0-3.
Interested to learn more?
Contact Us
For illustrations, downloads and the latest updates, visit the original published page.
View original Cellix reference